Local Goa News

Monday, May 23, 2016

Good news for diabetics in form of herbal drug

PANAJI: In one of its first, the Council for Scientific and Industrial Research (CSIR) has launched the first ayurvedic anti-diabetic drug BGR-34 in Goa.
The medicine has been researched and developed jointly by the CSIR Laboratories, National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP).
Addressing the media at the launch of the medicine in Panaji, senior principal scientist at CSIR-NBRI Dr A K S Rawat said that the country is facing the danger of being the diabetic capital of the world soon with more than 6 crore adults in India found to be diabetic already. The number is expected to reach to 10 crore by 2030.
“There is no effective solution for diabetes as yet. After having carried out in-depth studies on over 500 renowned ancient herbs, six best herbs listed in ayurvedic ancient texts for various ailments were identified for developing the medicine,” he said.
BGR-34, which is blood glucose regulator with 34 identified active phyto-constituents from herbal resources, contains daruharidra (berberis aristata), giloy (tinospora cordifolia), vijaysar (pterocarpus marsupium), gudmar (gymnema sylvestre), majeeth (rubia cordifoila) and methika (trigonella foenum-graecum).
Stating that modern diabetes drugs are known for side effects and toxicity, Rawat said that BGR-34 works by controlling blood sugar and limiting the harmful effects of other drugs. He said, “We are sure that eminent medical professionals will recommend it to their patients suffering from Type 2 diabetes mellitus for quicker and consistent response.”
He further said that the herbal drug has been priced at Rs five per tablet and is packed in a box of 100 tablets available in the market for Rs 500. “Compared to the latest DPP4 inhibitors globally, we have priced the tablet on the lower side to pass on the benefits to a larger section of the society and the poor can avail it,” he added.
Dr Sanjeev Kumar Ojha, senior scientist at CSIR-NBRI, said that the habit of eating more than what one can consume is at the core of embolic diseases. He said the greed to eat more, laziness to undertake physical activity and stress lead to metabolic diseases. “BGR-34 manages the lives of humans suffering from diabetes and enhances insulin secretion. The product has passed several tests and showed hypoglycemic activity in experimental subjects,” he said.
Dr Daya Nandan Mani, senior scientist at CSIR-CIMAP, said that pre-clinical studies of this anti-diabetic formulation revealed significant reduction in high blood sugar level in diabetes-induced experimental subjects. He said, “At the CSIR-CIMAP out-patient department (OPD), about 80 per cent of the diabetic patients who have been administered BGR-34 have responded positively.”
For the purpose of commercial production and market distribution, the CSIR has transferred the rights of the research technology to AIMIL Pharmaceuticals (I) Ltd.

NT Network Goa News

No comments:

Post a Comment